Home » ETF » BBP

BBP - BioShares Biotechnology Products ETF

Stock Price: $52.04 USD -0.84 (-1.58%)
Updated Apr 19, 2021 4:00 PM EDT - Market closed
Assets $29.08M
NAV $52.88
Expense Ratio 0.79%
PE Ratio n/a
Beta (5Y) 1.05
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Dec 20, 2017
1-Year Return -
Trading Day April 19
Last Price $52.04
Previous Close $52.88
Change ($) -0.84
Change (%) -1.58%
Day's Open 52.85
Day's Range 51.99 - 52.16
Day's Volume 1,009
52-Week Range 41.99 - 61.39

Fund Description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.

Asset Class
Portfolio-Multi Asset
Sector
Biotech
Region
North America
Inception Date
Dec 17, 2014
Exchange
NYSEARCA
Ticker Symbol
BBP
Index Tracked
BioShares Biotechnology Products Index

Top 10 Holdings

28.82% of assets
NameSymbolWeight
Agios PharmaceuticalsAGIO3.38%
Ligand PharmaceuticalsLGND3.34%
United TherapeuticsUTHR3.06%
BeiGeneBGNE3.01%
Radius HealthRDUS2.95%
Vanda PharmaceuticalsVNDA2.78%
Intra-Cellular TherapiesITCI2.72%
OmerosOMER2.55%
Enanta PharmaceuticalsENTA2.53%
Theravance BiopharmaTBPH2.50%
View All Holdings

News

Hide News
  • All
  • Videos
  • Conversation

As most corners of the market rallied on the slew of positive news, a few sectors scaled new highs. We have highlighted five ETFs from different sectors that hit all-time highs in the recent trading ses...

Other tickers mentioned: ITB, PRN, XRT, XSD
6 months ago - Zacks Investment Research

The S&P 500 posted its best third-quarter gains since 2010 with an advancement of 8.5%. The gains could continue as the October-December period is normally gainful for the market.

Other tickers mentioned: CLOU, ONLN, PBW
6 months ago - Zacks Investment Research

After a superb August, September turned gloomy for Wall Street.

Other tickers mentioned: DXJS, TAN, TAPR
6 months ago - Zacks Investment Research

The combination of lofty valuation, lack of additional fiscal stimulus package, election uncertainty and rising U.S.-China tensions weighed on investors' sentiment.

Other tickers mentioned: BETZ, EDUT, TAN
6 months ago - Zacks Investment Research

After a superb August, September looks gloomy for Wall Street. Still,

Other tickers mentioned: BETZ, IBBJ, PBD, RTM
6 months ago - Zacks Investment Research

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

Other tickers mentioned: ARKG, BBH, BTEC, CNCR, FBT, IBB, PBE ...
1 year ago - Zacks Investment Research

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Other tickers mentioned: BBC, BTEC, HEPA, SBIO
1 year ago - Zacks Investment Research

While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS: A...

Other tickers mentioned: FBT, IBB, SBIO
1 year ago - ETF Trends

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

Other tickers mentioned: ARKG, BTEC, SBIO, XBI
2 years ago - Zacks Investment Research

We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank #1 or 2 which are expected to outperform in the quarter ahead.

Other tickers mentioned: ASHR, ASHX, BTEC, KBA, PGJ, PTF, PXMG ...
2 years ago - Zacks Investment Research